Eli lilly was concerned by zyprexa side-effects from 1998-lif.

Eli Lilly was concerned by Zyprexa side-effects from 1998-Life & Style.
http://www.timesonline.co.uk/tol/life_and_style/health/article1295456.ece Cool in your code The online property showThis week: hidden Marylebone Houses or Jags? How will Prescott
be remembered?
BUSINESS
LIFE & STYLE
ARTS & ENTERTAINMENT
OUR PAPERS
AUDIO / VIDEO
CLASSIFIEDS
Giants meet to counter US powerStressed-out lawyer, 27, dies in late-night fall at Tate Concerns revealed in internal papers $4bn treatment linked to diabetes
ModernQuick-thinking pilot foils hijacker with the help of passengers Robin Pagnamenta, Health Industries Correspondent Penguin alert as whaler catches fire off Antarctic Eli Lilly, the American pharmaceutical giant that has consistently denied any link between Zyprexa, its antipsychotic drug, and diabetes, was concerned about the side-effects of the drug as early as 1998, according to documents seen by The Times. Zyprexa, or olanzapine, is a powerful drug used to treatschizophrenia and bipolar disorder, or manic depression. It is theworld’s fifth-bestselling drug and generated sales of $4.2 billion(£2.1 billion) last year — about 30 per cent of the company’stotal revenues.
Eli Lilly, one of America’s leading drugmakers, has been fightinga string of court actions related to the drug, which has beentaken by 20 million people worldwide since its launch in 1996,including thousands in the UK.
A series of leaked court documents seen by The Timessuggested that the company was aware of the risks of weight gain, hyperglycemia (high blood sugar) and diabetes associated with the drug but presented them as common problems across the whole class of schizophrenia drugs and not restricted to QUICKLINKS
2000, Robert Baker, a senior Lilly clinical research physician,e-mailed colleagues about a meeting of an academic advisoryboard he had attended in Atlanta. It had “reinforced myimpression that hyperglycemia remains quite a threat for Now Interactive
olanzapine and may merit increasing even further medical attention and marketing focus on this topic”. Dr Baker added: “[The board was] quite impressed by the magnitude of weightgain on olanzapine and implications for glucose.” Another internal document dated October 14-15, 1998, described the risk of weight gain as a “top threat” to Zyprexa.
This month Lilly agreed to pay up to $500 million to settle 18,000 FOCUS ZONE
lawsuits from people who claimed that they had developed diabetes or other diseases after taking Zyprexa.
Lilly has now agreed to pay out more than $1.2 billion to 28,500 people, who had claimed that their health was damaged by the drug. Another 1,200 lawsuits are continuing.
Upfront Rugby
Are Rugby fans getting the game they deserve?
A statement from Lilly said that the documents represented “atiny fraction of the more than 11 million pages of documents provided by Lilly as part of the litigation process. They do not accurately portray Lilly’s conduct nor represent an accurate viewof Lilly company strategy or activities.” It added that the documents were “selectively and illegallyleaked”. The company had done more than 23 years of researchon Zyprexa and had found no evidence of a causal link withdiabetes. “The link between schizophrenia and diabetespre-dates the development of any antipsychotic,” it said.
Eli Lilly added that Zyprexa’s labelling had always flagged Eli Lilly was concerned by Zyprexa side-effects from 1998-Life & Style.
http://www.timesonline.co.uk/tol/life_and_style/health/article1295456.ece Leading products:
CLASSIFIEDS
Eli Lilly: Zyprexa or Olanzapine; 2004 sales of $4.4 billion. Johnson & Johnson: Risperdal or risperidone; 2004 sales of $3.1 CARS OF THE WEEK
AstraZeneca: Seroquel or quetiapine; 2004 sales of $2 billion Audi A8 LWB
2005/54
Lamborghini Gallardo
Spyder
2006/56
ALSO IN HEALTH
Millions to benefit as first bionic eye comes to marketDid you know? Bentley Arnage 6.8 T
Viagra used to save the life of baby born 16 weeks early EXPLORE HEALTH
Mercedes-Benz GL420
CANCER FALL
Fall in breast cancer after women abandon HRT OUR EXPERT
Get AmbienCR 7 days Free
Discover the Difference our new Pill Makes - Get a Free Trial Now
My son is 19 and
started university last
September. He has
The Benefits of Quercetin
taken to wearing a hat
Looking for strength, energy and vitality? Get a free Sample of FRS.
because, he says, his
hair is falling out
More.
Instant Arthritis Relief
Amazing New Natural Remedy For Arthritis Will End Your Pain
ONLINE CONSULTATION
The Times doctor:
questions on ageing
Dr Thomas Stuttaford
answers your questions on
loneliness and dementia.
Send questions for his next
topic, Caesarean section
Extreme diet model dies six months after anorexic sisterDuchess will undergo a hysterectomy next monthI’ve had hep C for over 30years, says Anita RoddickCommon scents for healingGo to sleep - or you'll grow up short and fat

Source: http://playtime.rlbunn.com/Politics_and_Policy/Content_Text/SicknessCare/BadDrugs/Eli%20Lilly%20was%20concerned%20by%20Zyprexa%20side-effects%20from%201998-Lif...pdf

May june 2011 npo legal issues vol 12 version 2

COMPANIES ACT & REGULATIONS - IN OPERATION By Ricardo Wyngaard The Companies Act of 2008 (the Act) and Companies Regulations, 2011 (the ABOUT NPO LEGAL Regulations) came into operation on 01 May 2011. The Act has, to a large extent, been amended by the Companies Amendment Act, 2011. This brief article focuses on some of the key issues that should be taken note of by s21 companies

newsletter.cabinet-ores.com

Grosses délivrées REPUBLIQUE FRANCAISE aux parties le : AU NOM DU PEUPLE FRANCAIS COUR D'APPEL DE PARIS Pôle 1 - Chambre 2 ARRET DU 21 MARS 2012 Numéro d'inscription au répertoire général : 11/12942 Décision déférée à la Cour : Ordonnance du 21 Juin 2011 -Tribunal de Grande Instance de PARIS -RG n° 11/52963 APPELANTES NOVARTIS AG STE DE DROIT SUISSE agissant poursui

Copyright © 2011-2018 Health Abstracts